©2022 Stanford Medicine
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
Trial ID: NCT03181126
This dose-escalating study is to determine the safety, pharmacokinetics, and preliminary efficacy of venetoclax in combination with navitoclax and chemotherapy in adult and pediatric participants with relapsed/refractory acute lymphoblastic leukemia (ALL) or relapsed/refractory lymphoblastic lymphoma. A safety expansion cohort of approximately 20 patients may be enrolled in addition to the 50 participants in dose-escalation cohort.
A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
- Must have relapsed or refractory acute lymphoblastic leukemia (ALL) or relapsed or
refractory lymphoblastic lymphoma (LL). Refractory is defined as persistent disease
after at least 2 courses of chemotherapy.
- Participants with ALL with Philadelphia chromosome or with an ABL class
targetable fusion are eligible.
- Participants with LL must have radiographic evidence of disease
- Participants <= 18 years of age who do not have a standard of care treatment option
- Must weigh greater than or equal to 20 kg.
- Must be able to swallow pills.
- Must have adequate hepatic and kidney function.
- Must have adequate performance status:
- Participants less than or equal to 16 years of age: Lansky greater than or equal
- Participants greater than 16 years of age: Karnofsky greater than or equal to 50
or Eastern Cooperative Oncology Group (ECOG) less than 3.
- Participant has central nervous system (CNS) disease with cranial involvement that
- Participants who are less than 100 days post-transplant, or greater than 100 days
post-transplant with active graft versus host disease (GVHD), or are still continuing
post-transplant immunosuppressant therapy within 7 days prior to the first dose of
- Participants who have received any of the following prior to the first dose of study
- Inotuzumab within 30 days (if participant received inotuzumab > 30 days prior to
Day 1, must have ALT, AST and bilirubin < ULN).
- A biologic agent (i.e., monoclonal antibodies) for anti-neoplastic intent within
- CAR-T infusion or other cellular therapy within 30 days
- Any anti-cancer therapy including blinatumomab, chemotherapy, radiation therapy
targeted small molecule agents or investigational agents within 14 days, or 5
half-lives, whichever is shorter
- Exception: Philadelphia Chromosome (Ph)+ ALL subjects on TKIs at Screening
may enroll and remain on Tyrosine Kinase Inhibitor (TKI) therapy to control
disease. Participants on venetoclax at screening may enroll and remain on
- Steroid therapy for anti-neoplastic intent within 5 days
- Hydroxyurea that is ongoing (hydroxyurea is permitted up to the first dose)
- A strong or moderate CYP3A inhibitor or inducer within 7 days
- Aspirin within 7 days, or 5 half-lives, whichever is longer
- An excluded antiplatelet/anticoagulant drug or a herbal supplement that affects
platelet function within 7 days, or 5 half-lives, whichever is longer
- Participants with malabsorption syndrome or any other condition that precludes enteral
School of Medicine
300 Pasteur Drive
Stanford, CA 94305